Related Experiment Video
Updated: Dec 31, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Genetic testing in patients with hypertrophic cardiomyopathy
Insights
Hypertrophic cardiomyopathy (HCM), a common inherited heart condition, has a complex genetic basis. Next Generation Sequencing (NGS) offers a faster, cost-effective way to identify genetic variants, aiding clinical management and future disease disruption.
Area of Science:
- Cardiovascular Genetics
- Genomic Medicine
- Molecular Cardiology
Background:
- Hypertrophic cardiomyopathy (HCM) is a prevalent inherited cardiac condition affecting up to 1 in 200 individuals.
- HCM is typically autosomal dominant, linked to sarcomeric protein gene variants, but over 2,000 mutations across 27 genes are associated with the disease.
- Conventional genetic analysis methods are time-consuming and costly due to genetic and allelic heterogeneity.
Purpose of the Study:
- To highlight the complexity of hypertrophic cardiomyopathy genetics.
- To introduce Next Generation Sequencing (NGS) as an efficient diagnostic tool for HCM.
- To discuss the challenges and benefits of genetic variant interpretation in HCM.
Main Methods:
- Utilized Next Generation Sequencing (NGS) for rapid, broad-scale genomic analysis of HCM-associated genes.
- Discussed the challenges in interpreting numerous genetic variants of uncertain significance identified through large-scale screening.
- Reviewed the role of clinical scoring systems in predicting genetic testing yield.
Main Results:
- NGS enables analysis of numerous genes or whole genomes cost-effectively and accurately.
- Genetic screening yields vary (20-40%), necessitating careful interpretation of identified variants.
- Genetic testing facilitates mutation-specific family testing and clinical management.
Conclusions:
- Identifying the genetic basis of HCM is crucial for understanding disease mechanisms.
- Genetic insights into HCM offer opportunities for developing future therapeutic strategies.
- NGS-based genetic testing is a valuable tool for HCM diagnosis, management, and research.
Abstract:
Hypertrophic cardiomyopathy (HCM) is a frequent inherited heart disease with an estimated prevalence of up to 1 in 200 individuals. In the majority of cases, HCM is inherited as an autosomal dominant genetic trait with pathogenic variants detected in sarcomeric proteins. Nevertheless, the genetic basis of HCM is more complex. More than 2 000 mutations in 27 genes have been described in association with HCM. The genetic and allelic heterogeneity makes molecular analysis by conventional methods time-consuming and expensive. Next Generation Sequencing (NGS) based genomic testing allows rapid analysis of a large number of genes or even a whole genome at similar cost and accuracy to conventional sequencing methods. Screening large numbers of genes results in the identification of many genetic variants of uncertain significance and makes the results interpretation difficult. The process of classification the genetic variants is very complex. Genetic screening is an important tool for clinical management of HCM patients and enables mutation-specific confirmatory testing of the appropriate family members. The yield of genetic testing is variable, about 20-40 %. For predicting the diagnostic yield of genetic testing, clinical scoring systems have been developed. Identifying the genetic basis of HCM creates remarkable opportunities to understand how disease develops, and by extension, how to disrupt the disease progression in the future.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Dysrhythmias V: Evaluating Dysrhythmias
Cardiomyopathy II: Dilated Cardiomyopathy
Myocarditis II: Clinical Features and Diagnostic Tests
Mitral Stenosis II: Clinical features and Diagnostic Tests

